Arcutis Biotherapeutics (ARQT) insider Patrick Burnett plans sale of 955 shares

Rhea-AI Filing Summary

Patrick Burnett filed to sell common stock of Arcutis Biotherapeutics under a planned transaction. The filing lists 955 shares of common stock to be sold through Merrill Lynch, with an anticipated sale date of 08/03/2026 on NASDAQ.

The filing also references the source of these shares as restricted stock vesting on 08/01/2026 and discloses prior sales over the past three months: 684 shares for 16,149.65 on 05/04/2026 and 222 shares for 4,673.10 on 05/11/2026.

Key Figures

Planned shares to be sold: 955 shares Planned sale date: 08/03/2026 Restricted stock vesting date: 08/01/2026 +4 more

7 metrics

Planned shares to be sold 955 shares Common stock to be sold through Merrill Lynch on 08/03/2026

Planned sale date 08/03/2026 Anticipated transaction date for 955 shares on NASDAQ

Restricted stock vesting date 08/01/2026 Source of 955 shares reported as restricted stock vesting

Prior sale shares 684 shares Common stock sold on 05/04/2026 for 16,149.65

Prior sale amount 16,149.65 Consideration for 684 shares sold on 05/04/2026

Second prior sale shares 222 shares Common stock sold on 05/11/2026 for 4,673.10

Second prior sale amount 4,673.10 Consideration for 222 shares sold on 05/11/2026

Key Terms

Form 144, restricted stock vesting, common stock

3 terms

Form 144 regulatory

"The Form 144 discloses that Patrick Burnett plans to sell 955 shares"

Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.

restricted stock vesting financial

"The filing also references the source of these shares as restricted stock vesting"

Restricted stock vesting is the timetable and conditions under which shares granted to employees or insiders become fully owned and can be sold, typically requiring continued work or meeting performance goals. It matters to investors because large blocks of shares can become tradable at once, which can change share supply and price, and because vesting aligns insiders’ incentives with the company’s long‑term performance—think of it like a timed unlock that both rewards and locks in key people.

common stock financial

"plans to sell 955 shares of Arcutis Biotherapeutics common stock"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/03/2026 - 05:07 PM Accepted by SEC EDGAR 08/03/2026 - 05:07 PM Learn about SEC filing dates

FAQ

What does Arcutis Biotherapeutics (ARQT) Form 144 filed by Patrick Burnett disclose?

The Form 144 discloses that Patrick Burnett plans to sell 955 shares of Arcutis Biotherapeutics common stock, sourced from restricted stock vesting on 08/01/2026, with sales expected through Merrill Lynch on NASDAQ.

How many ARQT shares are planned for sale in the new Form 144?

The filing shows a planned sale of 955 shares of Arcutis Biotherapeutics common stock. These shares are to be sold through Merrill Lynch, with an anticipated transaction date of 08/03/2026 on NASDAQ.

What prior ARQT stock sales by Patrick Burnett are reported in this Form 144?

The filing lists two prior sales: 684 shares for 16,149.65 on 05/04/2026 and 222 shares for 4,673.10 on 05/11/2026. Both relate to Arcutis Biotherapeutics common stock sold within the past three months.

What is the source of the ARQT shares Patrick Burnett plans to sell?

The Form 144 identifies the source as restricted stock vesting dated 08/01/2026. The 955 shares of Arcutis Biotherapeutics common stock planned for sale originate from this vesting event.

Through which broker and market will Patrick Burnett’s ARQT shares be sold?

The filing specifies that the 955 shares of Arcutis Biotherapeutics common stock are to be sold through Merrill Lynch, with the planned transaction to occur on the NASDAQ market.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Merrill Lynch 8890 Lyra Drive 5th Floor Columbus OH 43240	955	24941.54	125083374	08/03/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	08/01/2026	Restricted Stock Vesting	Arcutis Biotherapeutics			955	08/01/2026	NA

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Patrick Burnett 3027 Townsgate Rd Suite 300 Westlake Village CA 91361	Common	05/04/2026	684	16149.65
Patrick Burnett 3027 Townsgate Rd Suite 300 Westlake Village CA 91361	Common	05/11/2026	222	4673.1

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)